Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies

Smita Vaidya, Chu Chi Wang, Kristene Gugliuzza, Jay C. Fish

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Introduction. Antiphospholipid antibody syndrome (APAS) is a condition associated with recurrent arterial and venous thrombosis, recurrent abortions, and thrombocytopenia either with or without lupus. In this study we have evaluated the impact of APAS on the renal transplant outcome of 174 patients. Method. Patients' APAS status was determined by the presence of anticardiolipin antibodies (ACA) and a history of clotting disorders. Serum samples from each patient were tested for the presence of ACA by the ELISA method. Transplant outcomes were monitored for ≤ 1 yr. Results. Of 174 patients, 78 received renal transplants. Six of these 78 patients had APAS as evidenced by either recurrent microrenal angiopathy (2 patients), thrombocytopenia (1 patient) or frequent A-V shunt thrombosis (3 patients) along with high titers of ACA of IgM, IgG, or both subtypes at the time of their transplants. Each of these 6 patients thrombosed their renal allografts within a week of their transplants. The other 72 transplanted patients with no APAS were all doing well 1 yr post-transplant. The association between APAS and post-transplant renal thrombosis among these patients is highly significant (p < 0.0001). In contrast, no association was discerned between post-transplant thrombosis and prior sensitization to HLA. Conclusion. Our data demonstrates that patients with APAS are at high risk for development of post-transplant renal thrombosis.

Original languageEnglish (US)
Pages (from-to)439-444
Number of pages6
JournalClinical Transplantation
Volume12
Issue number5
StatePublished - Oct 1998

Fingerprint

Antiphospholipid Antibodies
Thrombosis
Antiphospholipid Syndrome
Transplants
Kidney
Anticardiolipin Antibodies
Habitual Abortion
Venous Thrombosis
Thrombocytopenia
Allografts
Immunoglobulin M
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies. / Vaidya, Smita; Wang, Chu Chi; Gugliuzza, Kristene; Fish, Jay C.

In: Clinical Transplantation, Vol. 12, No. 5, 10.1998, p. 439-444.

Research output: Contribution to journalArticle

@article{f6588035fbc147ac995410ac8a82954b,
title = "Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies",
abstract = "Introduction. Antiphospholipid antibody syndrome (APAS) is a condition associated with recurrent arterial and venous thrombosis, recurrent abortions, and thrombocytopenia either with or without lupus. In this study we have evaluated the impact of APAS on the renal transplant outcome of 174 patients. Method. Patients' APAS status was determined by the presence of anticardiolipin antibodies (ACA) and a history of clotting disorders. Serum samples from each patient were tested for the presence of ACA by the ELISA method. Transplant outcomes were monitored for ≤ 1 yr. Results. Of 174 patients, 78 received renal transplants. Six of these 78 patients had APAS as evidenced by either recurrent microrenal angiopathy (2 patients), thrombocytopenia (1 patient) or frequent A-V shunt thrombosis (3 patients) along with high titers of ACA of IgM, IgG, or both subtypes at the time of their transplants. Each of these 6 patients thrombosed their renal allografts within a week of their transplants. The other 72 transplanted patients with no APAS were all doing well 1 yr post-transplant. The association between APAS and post-transplant renal thrombosis among these patients is highly significant (p < 0.0001). In contrast, no association was discerned between post-transplant thrombosis and prior sensitization to HLA. Conclusion. Our data demonstrates that patients with APAS are at high risk for development of post-transplant renal thrombosis.",
author = "Smita Vaidya and Wang, {Chu Chi} and Kristene Gugliuzza and Fish, {Jay C.}",
year = "1998",
month = "10",
language = "English (US)",
volume = "12",
pages = "439--444",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies

AU - Vaidya, Smita

AU - Wang, Chu Chi

AU - Gugliuzza, Kristene

AU - Fish, Jay C.

PY - 1998/10

Y1 - 1998/10

N2 - Introduction. Antiphospholipid antibody syndrome (APAS) is a condition associated with recurrent arterial and venous thrombosis, recurrent abortions, and thrombocytopenia either with or without lupus. In this study we have evaluated the impact of APAS on the renal transplant outcome of 174 patients. Method. Patients' APAS status was determined by the presence of anticardiolipin antibodies (ACA) and a history of clotting disorders. Serum samples from each patient were tested for the presence of ACA by the ELISA method. Transplant outcomes were monitored for ≤ 1 yr. Results. Of 174 patients, 78 received renal transplants. Six of these 78 patients had APAS as evidenced by either recurrent microrenal angiopathy (2 patients), thrombocytopenia (1 patient) or frequent A-V shunt thrombosis (3 patients) along with high titers of ACA of IgM, IgG, or both subtypes at the time of their transplants. Each of these 6 patients thrombosed their renal allografts within a week of their transplants. The other 72 transplanted patients with no APAS were all doing well 1 yr post-transplant. The association between APAS and post-transplant renal thrombosis among these patients is highly significant (p < 0.0001). In contrast, no association was discerned between post-transplant thrombosis and prior sensitization to HLA. Conclusion. Our data demonstrates that patients with APAS are at high risk for development of post-transplant renal thrombosis.

AB - Introduction. Antiphospholipid antibody syndrome (APAS) is a condition associated with recurrent arterial and venous thrombosis, recurrent abortions, and thrombocytopenia either with or without lupus. In this study we have evaluated the impact of APAS on the renal transplant outcome of 174 patients. Method. Patients' APAS status was determined by the presence of anticardiolipin antibodies (ACA) and a history of clotting disorders. Serum samples from each patient were tested for the presence of ACA by the ELISA method. Transplant outcomes were monitored for ≤ 1 yr. Results. Of 174 patients, 78 received renal transplants. Six of these 78 patients had APAS as evidenced by either recurrent microrenal angiopathy (2 patients), thrombocytopenia (1 patient) or frequent A-V shunt thrombosis (3 patients) along with high titers of ACA of IgM, IgG, or both subtypes at the time of their transplants. Each of these 6 patients thrombosed their renal allografts within a week of their transplants. The other 72 transplanted patients with no APAS were all doing well 1 yr post-transplant. The association between APAS and post-transplant renal thrombosis among these patients is highly significant (p < 0.0001). In contrast, no association was discerned between post-transplant thrombosis and prior sensitization to HLA. Conclusion. Our data demonstrates that patients with APAS are at high risk for development of post-transplant renal thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=0031663955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031663955&partnerID=8YFLogxK

M3 - Article

C2 - 9787955

AN - SCOPUS:0031663955

VL - 12

SP - 439

EP - 444

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 5

ER -